Scarica l'app Stockscreener
1.24
0.00%
0.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BNGO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.24
Aprire:
$1.24
Volume 24 ore:
16,232
Relative Volume:
0.06
Capitalizzazione di mercato:
$14.21M
Reddito:
$28.51M
Utile/perdita netta:
$-26.40M
Rapporto P/E:
-0.2265
EPS:
-5.4756
Flusso di cassa netto:
$-16.35M
1 W Prestazione:
+5.98%
1M Prestazione:
+2.48%
6M Prestazione:
-31.49%
1 anno Prestazione:
-66.67%
Intervallo 1D:
$1.2383
$1.26
Intervallo di 1 settimana:
$1.1646
$1.2999
Portata 52W:
$1.06
$5.50
Bionano Genomics Inc Stock (BNGO) Company Profile
Nome
Bionano Genomics Inc
Settore
Industria
Telefono
(858) 888-7600
Indirizzo
9540 TOWNE CENTRE DRIVE, SAN DIEGO, CA
Compare BNGO vs ISRG, BDX, ALC, MDLN, RMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BNGO
Bionano Genomics Inc
|
1.2383 | 14.11M | 28.51M | -26.40M | -16.35M | -5.4756 |
ISRG
Intuitive Surgical Inc
|
441.03 | 155.16B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
147.11 | 40.68B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
67.96 | 33.06B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
36.65 | 31.30B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
207.17 | 30.18B | 5.54B | 1.52B | 1.74B | 10.37 |
Bionano Genomics Inc Stock (BNGO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-15 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-09-10 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-12-12 | Ripresa | BTIG Research | Buy |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2021-06-16 | Iniziato | BTIG Research | Buy |
| 2020-09-24 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-04-08 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Bionano Genomics Inc Borsa (BNGO) Ultime notizie
Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia - The Manila Times
Leukemia study: genome scan finds abnormalities in 97.8% of T-ALL cases - Stock Titan
Bionano Genomics Q4 2026 earnings preview - MSN
BNGO News | BIONANO GENOMICS INC (NASDAQ:BNGO) - ChartMill
Earnings call transcript: Bionano Genomics sees Q1 revenue growth, stock edges up - Investing.com Canada
Q1 2026 Bionano Genomics Inc Earnings Call Transcript - GuruFocus
Bionano outlines $30M-$33M 2026 revenue guidance as it expects flow cell supply to improve - MSN
Bionano Genomics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:BNGO) 2026-05-16 - Seeking Alpha
Bionano Genomics, Inc. (NASDAQ:BNGO) Q1 2026 Earnings Call Transcript - Insider Monkey
BNGO Should I Buy - Intellectia AI
Bionano Genomics shareholders elect directors and approve proposals at annual meeting - Investing.com Nigeria
Bionano Genomics (NASDAQ: BNGO) director awarded 9,149 options - Stock Titan
Bionano Genomics (BNGO) director granted 9,149 stock options at $1.19 - Stock Titan
Bionano Genomics (BNGO) director awarded 9,149 stock options vesting over 12 months - Stock Titan
Bionano Genomics (BNGO) director receives grant of 9,149 stock options at $1.19 - Stock Titan
Bionano Genomics (BNGO) director receives stock option grant for 9,149 shares - Stock Titan
BioNano Genomics Stockholders Approve 2026 Annual Meeting Proposals - TipRanks
Bionano Genomics 1Q Rev $6.7M >BNGO - Moomoo
Bionano Genomics (NASDAQ: BNGO) reports 2026 shareholder voting results - Stock Titan
Bionano Genomics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Bionano Reports First Quarter 2026 Results and Provides a Business Update - The Manila Times
Bionano Genomics Inc (BNGO) Q1 2026 Earnings Call Highlights: Re - GuruFocus
Is Bionano Genomics (BNGO) Undervalued After Q1 2026? EPS not di - GuruFocus
Bionano Genomics, Inc. (BNGO) reports Q1 loss, tops revenue estimates - MSN
Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
BNGO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bionano Genomics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
BNGO: Q1 2026 saw 4% revenue growth, record flow cell sales, and improved gross margin, with strong outlook - TradingView
Earnings call transcript: Bionano Genomics Q1 2026 shows revenue growth By Investing.com - Investing.com South Africa
Earnings call transcript: Bionano Genomics Q1 2026 shows revenue growth - Investing.com
BNGO: Q1 2026 saw revenue and margin growth, record flow cell sales, and strengthened reimbursement - TradingView
Transcript: Bionano Genomics Q1 2026 Earnings Conference Call - Yahoo Finance
BIONANO GENOMICS ($BNGO) Releases Q1 2026 Earnings - Moomoo
Bionano Genomics Q1 revenue up 4%, margin improves; to retire convertible debt - TradingView
Bionano Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Bionano Genomics (NASDAQ: BNGO) posts Q1 2026 loss and warns on going concern - Stock Titan
Bionano Genomics, Inc. Provides Revenue Guidance for the Second Quarter of the Year 2026 - marketscreener.com
Bionano Genomics (BNGO) posts Q1 2026 loss on $6.7M revenue and lifts OGM reimbursement - Stock Titan
Bionano Genomics Q1 2026 Earnings Call Transcript - MarketBeat
バイオナノ、2026年第1四半期の決算を発表し事業状況を報告 - Moomoo
TradingKey - TradingKey
Bionano Genomics Inc (BNGO) Q1 2026 Earnings Report Preview: Wha - GuruFocus
BNGO Q1'26 Earnings: EPS estimate is (0.88) USD - TradingView
Bionano Genomics Inc expected to post a loss of 95 cents a shareEarnings Preview - TradingView
Bionano raises 2025 OGM installation target to 25 as consumables and software revenue climbs 16% - MSN
Bionano Genomics Inc Azioni (BNGO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.16%
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):